RxDoctor Payments Data

Ann Rybolt, MD

Internal Medicine · Chattanooga, TNNPI 1750375333

Payments from drug & device makers

$7,990in general payments, 2019–2025

Across 516 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Amgen$833
  • Pfizer$712
  • AbbVie$620
  • Astellas Pharma US Inc$509
  • GSK$475
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$7,92899%
  • Education$621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,990 in reported general payments places this provider in the 90th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$115,577
Medicare patients
163
Services billed
2,168

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban130$113,954
OzempicSemaglutide51$71,129
MyrbetriqMirabegron36$34,542
RybelsusSemaglutide14$29,855
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$27,624
XareltoRivaroxaban30$22,307
Repatha SureclickEvolocumab22$14,219
FarxigaDapagliflozin Propanediol12$12,197
Tresiba Flextouch U-100Insulin Degludec17$9,060
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$6,079
NexlizetBempedoic Acid/Ezetimibe12$5,588
JanuviaSitagliptin Phosphate11$5,285
Atorvastatin Calcium295$3,860
Ezetimibe88$3,237
Rosuvastatin Calcium187$2,950

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$712$113,954130 claims
Novo NordiskOzempic, Rybelsus$1,137$100,98465 claims
Astellas Pharma US IncMyrbetriq$509$34,54236 claims
GSKTrelegy Ellipta, Anoro Ellipta$475$33,70335 claims
Johnson & JohnsonXarelto$356$22,30730 claims
AstraZenecaFarxiga$294$12,19712 claims
Esperion Therapeutics, Inc.Nexlizet$45$5,58812 claims
MerckJanuvia$124$5,28511 claims
AbbVieSynthroid$620$1,64912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →